Other Anti-VEGF/Anti-PDGF Combination Drugs in the Pipeline for Treatment of AMD
VEGF and PDGF are two common and critical pathways implicated in serious retinal diseases and a combination treatment of anti-PDGF and anti-VEGF agents may prove more effective in the treatment of wet AMD than anti-VEGF monotherapy, particularly in recalcitrant disease. This avenue is being investigated by several other companies that are developing their own anti-VEGF/anti-PDGF platforms.
Designed ankyrin repeat proteins (DARPins) provide a platform for the creation of drugs with multiple binding target proteins, and abicipar pegol (Allergan) is part of this new class of small molecule therapeutics. The company is collaborating with Molecular Partners in the development of an anti-VEGF/anti-PDGF DualDARPin that pairs VEGF-targeting abicipar with another DARPin that targets PDGF for the treatment of patients with AMD.
Two phase 3 studies initiated in 2015 will compare this DualDARPin with ranibizumab (Lucentis, Genentech). These randomized, double-masked, parallel-group, active-controlled studies consist of approximately 400 clinical study sites in roughly 30 countries.
DE-120 (Santen) is a small molecule dual tyrosine kinase receptor inhibitor for both VEGF and PDGF signaling pathways. DE-120 belongs to a class of active small molecules that inhibit the activity of receptor tyrosine kinases involved in the angiogenic process. Several such inhibitors have been approved by the FDA and other healthcare authorities for the treatment of various cancers. As a single anti-VEGF/anti-PDGF agent, DE-120 has the potential to provide a synergic antiangiogenic effect and reduce the potential side effects associated with intravitreal injection procedures.
Santen is conducting a phase 2 clinical trial in the United States to evaluate the safety and efficacy of intravitreal DE-120 as monotherapy and along with a single injection of aflibercept (Eylea, Regeneron) in subjects with treatment-naïve active subfoveal CNV secondary to AMD.
TWO MORE BEING INVESTIGATED
Carl C. Awh, MD, and Jeffrey S. Heier, MD, discuss two other anti-VEGF/anti-PDGF combination therapies in this issue: X-82 (Tyrogenex), an orally administered small-molecule tyrosine kinase inhibitor derived from a cancer drug that inhibits VEGF and PDGF receptors here; and REGN2176-3 (Regeneron), which consists of the anti-VEGF drug aflibercept (Eylea, Regeneron) and an antibody to the PDGF receptor (rinucumab, Regeneron) here.
RXi Pharmaceuticals Announces Completion of Enrollment of Phase 1/2 Clinical Trial with RXI-109 for Retinal Scarring
RXi Pharmaceuticals announced the completion of enrollment in its phase 1/2 study RXI-109-1501. This multicenter, multidose, dose escalation trial is being conducted in patien…
pSivida Submits Marketing Authorization Application for Approval of Durasert 3-Year Treatment for Posterior Segment Uveitis in the EU
pSivida Corp. has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA), seeking approval to market the company’s Durasert 3-year …
Bausch + Lomb Unveils AMD Virtual Experience with State-of-the-Art Technology at Optometry’s Meeting
Bausch + Lomb announced the launch of a new virtual reality tool using state-of-the-art technology. The Age-Related Macular Degeneration (AMD) Virtual Experience, unveiled dur…